Related Experiment Videos
Beneficial effect of pneumococcal vaccination on otitis media in children over two years old
Insights
Pneumococcal vaccines like Pneumovax may help prevent acute otitis media in children aged 2-5 years. The vaccine showed a 24% reduction in total cases and a 40% decrease in recurrent ear infections.
Area of Science:
- Pediatrics
- Immunology
- Infectious Diseases
Background:
- Acute otitis media (AOM) is a common childhood infection, particularly in children attending daycare.
- Pneumococcal bacteria are a significant cause of AOM.
- Vaccination strategies are explored to reduce the incidence and recurrence of AOM.
Purpose of the Study:
- To evaluate the efficacy of a 14-valent pneumococcal vaccine (Pneumovax) in preventing acute otitis media in young children.
- To assess the vaccine's impact on both total and recurrent episodes of AOM.
- To determine the duration of protective effect post-vaccination.
Main Methods:
- A double-blind, placebo-controlled trial involving 405 children aged 6 months to 5 years.
- Participants were matched by age and history of otitis media.
- Children attended daycare centers to ensure similar exposure to respiratory pathogens.
Main Results:
- A 24% reduction in the total incidence of AOM was observed in children aged 2-5 years (P < 0.05).
- Recurrent AOM episodes decreased by 40% in the vaccinated group aged 2-5 years.
- Vaccine efficacy was significant within the first year post-vaccination but waned thereafter; no effect was seen in children under 2 years.
Conclusions:
- The 14-valent pneumococcal vaccine (Pneumovax) is effective in reducing the incidence of acute otitis media in children aged 2-5 years.
- The vaccine demonstrates particular benefit in preventing recurrent episodes of otitis media in this age group.
- The protective effect is time-limited, emphasizing the need for timely vaccination and potential boosters.
Abstract:
The effect of immunization with a 14-valent pneumococcal vaccine (Pneumovax) was studied in a double-blind trial in which 405 children between the ages of 6 months and 5 years were matched in vaccine/control pairs according to age and history of otitis media. The fact that all the children attended day-care centres ensured that both vaccinees and controls were similarly exposed to upper respiratory tract pathogens. The total incidence of acute otitis media was reduced during a 2-year follow-up period by 24% (P less than 0.05) among those vaccinated between the ages of 2 and 5. For recurrent episodes a decrease by 40% was noted. Protective efficacy was demonstrable during the first post-vaccinational year, but not when more than 1 year had lapsed after the vaccination. These findings suggest that, while the vaccine had not effect on children under 2 years old, it may be a useful aid in preventing recurrent attacks of otitis media in children between 2 and 5 years of age.